Clinical Trial Update: Topical Infliximab in Autoimmune Eyes With Keratoprosthesis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of topical infliximab for autoimmune eye conditions with keratoprosthesis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucous Membrane Pemphigoid
• Stevens-johnson Syndrome
• Toxic Epidermal Necrolysis

Drugs mentioned

• Infliximab (infliximab)

Snippet

Sponsor: James Chodosh, MD, MPH | Conditions: Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis (Lyell) Syndrome | Phase 1, Phase 2 | Status: WITHDRAWN